SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports that Nvidias board may remove Jensen Huang amid allegations involving workplace relationships and suspected Chinese intelligence links have dominated discussion, with traders debating leadership and governance risks while others dismiss the reports as unconfirmed and view the selloff as a buying opportunity. The boards reported deliberations and possible congressional scrutiny have intensified uncertainty around Huangs future, though no removal is confirmed.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Reports that Nvidias board may oust Jensen Huang amid misconduct and national-security scrutiny have fueled bets that customers and capital could shift toward AMD. Traders are divided over whether the move signals lasting market-share gains or is a sentiment-driven rally, arguing Nvidias leadership turmoil does not by itself change chip competitiveness.

GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF

GraniteShares 2x Long NVDA Daily ETF

Reports and speculation that Nvidias board may oust CEO Jensen Huang are driving attention, with traders debating whether the controversy and related selloff are a buying opportunity or a sign of further downside. Many are buying the dip in NVDL ahead of Nvidia earnings, while noting that the ETFs 2 daily exposure can magnify moves in either direction.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

AMATs upcoming quarterly earnings report has traders focused on equipment orders and guidance as a read-through on whether AI-driven fab spending is holding up. The community is split between optimism about chipmaking demand and concern that capex could slow, with recent price strength prompting both rebound hopes and caution about the outlook.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos upcoming earnings report has traders focused on whether AI infrastructure orders will translate into durable revenue and cash flow, or reflect hyperscalers potentially lumpy data-center spending. Optimists point to strong networking demand, while skeptics highlight margin and inventory risks and question whether the order momentum is sustainable.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs quarterly results highlighted rapid growth in its Quake AI infrastructure business and a first positive adjusted EBITDA quarter, fueling a sharp rally. Traders are debating whether high short interest could amplify the move, while others point to the softer next-quarter outlook and uncertainty around financing further data-center expansion.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Strong Q3 growth led by Recorlev and raised revenue expectations, including an accelerated long-term sales outlook, are driving bullish discussion around Xeriss earnings-based rerating. Some traders also speculate about a buyout, but that remains unconfirmed, while others warn the sharp rally could pull back.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors rally is centered on the FDAs November 22 decision on deramiocel for Duchenne muscular dystrophy, with managements confidence in the trial data and comments about possible labeling fueling optimism. Traders are also discussing analyst upgrades and a potential short squeeze, while others stress that approval remains uncertain given prior FDA concerns and the binary nature of the decision.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMHs rebound is drawing attention as traders point to CoreWeaves upbeat outlook as support for AI-chip demand, while reported uncertainty around Nvidia CEO Jensen Huang and doubts about debt-funded AI spending keep some traders cautious. Others see the move as a buying opportunity, with chip stocks rebounding despite Nvidia-specific pressure.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

China-related security allegations and congressional scrutiny are a major focus, with traders debating whether the resulting pressure is overdone or signals lasting risk. Attention is also building around Webulls upcoming quarterly results: bulls cite growth and profitability and expect a recovery, while skeptics point to weak trading and persistent selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes OKYO Pharma (OKYO) a New Buy Stock

OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) has earned an average recommendation of 'Hold' from the five analysts that are presently covering the firm, MarketBeat.com reports...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 272,194 shares, an increase of 31.9% from the March 31st total of 206,345 shares. Based on...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have been given an average rating of "Hold" by the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant drop in short interest in February. As of February 27th, there was short interest totaling 435,430...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler

Piper Sandler raised OKYO Pharma to a "strong-buy" rating in a report on Friday...

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com...

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited - Ordinary Shares - New

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

Equity

Bearish Sentiment

Shares of OKYO Pharma (OKYO) jumped 8% on Monday morning after the company said that it is now planning to advance to a multiple-ascending-dose (MAD) clinical trial for its lead drug candidate Urcosimod.Urcosimod is being developed to treat neuropathic corneal pain (NCP), a condition that causes severe pain and sensitivity of the eyes, face, or head, and is thought to result from nerve damage to the cornea combined with inflammation.In July, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://okyopharma.com/okyo-pharma-announces-registration-pathway-with-100-patient-multi-center-clinical-trial-of-urcosimod-in-neuropathic-corneal-pain/">announced</a> data from a mid-stage trial of Urcosimod in 17 NCP patients. After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% Urcosimod showed greater than 80% reduction in neuropathic corneal pain in that study, as measured by visual analog scale.Okyo said on Monday that it is now focused on advancing to a multiple-ascending-dose (MAD) clinical trial designed to enroll approximately 100 NCP patients across several U.S. clinical sites. The purpose of the trial is to identify the optimal registration dose for Urcosimod for future late-stage trials and to develop an understanding of the drug’s characteristics.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OKYO">OKYO stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_1_09_35_PM_png_4bfce5981c.webp" alt="OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that they now see a “clear route forward.”<stembedurl>https://stocktwits.com/rp6577/message/629485633</stembedurl>The company said that it expects data from this new trial in 2026, and negotiations are underway with several clinical sites in the U.S. Okyo continues to progress toward a meeting with the U.S. Food and Drug Administration (FDA) to discuss requirements for an approvable drug to treat NCP and to define the primary endpoint required for potential registration, it said.“Our next &nbsp;MAD clinical trial is designed to give us the data needed to define an optimal registration pathway for urcosimod, and we are moving rapidly to initiate this study. With Fast-Track designation in place and a constructive engagement anticipated with FDA, we are well-positioned to bring this novel therapy closer to patients in need,” said CEO Gary S Jacob.OKYO stock is up 85% this year and approximately 112% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-awarded-with-yet-another-price-target-hike-after-waymo-partnership/chDQu3aR32s">Lyft Awarded With Yet Another Price Target Hike After Waymo Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.

Pharma Limited

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

OKYO News